Trillium Therapeutics Inc. announced the following key additions to its leadership team:

• Blythe Thomson, MD, Executive Medical Director
• Jane E. Cole, RN, Senior Director, Clinical Operations
• Brian E. Jahns, PharmD, Senior Vice President, Commercial and Business Development

OBIO Pre-CAAP Company MedStack announced an enterprise platform collaboration with Sinai Health System to better serve hospitals and digital health entrepreneurs who want to introduce their technology into hospital environments.

VBI Vaccines Inc., a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that the first patient has been dosed in a Phase 1/2a clinical study of VBI-1901 for the treatment of recurrent glioblastoma multiforme (rGBM).

ImmunoBiochem, a CAAP company solving the problem of tumor heterogeneity won 2nd place at the highly competitive RESI San Francisco Innovation Challenge last week.

CAAP company ImmunoBiochem, which is solving the problem of tumor heterogeneity by targeting unique proteins enriched in the secretomes of cancer cells with Antibody Drug Conjugates (ADCs) won 2nd place at the highly competitive RESI San Francisco Innovation Challenge

The Canadian Innovation Awards celebrate the best and brightest in the Canadian technology community. Now in its seventh year, the awards acknowledge outstanding startups, innovative businesses and influential individuals. Trexo Robotics advanced to the finals in the New Startup category.

HCell Inc. (Hcell), a biotechnology company focusing on Alopecia Areata in the Pediatric Population, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to HC017AA for the treatment of pediatric patients with Alopecia Areata, a devastating hair loss disease.

Adapsyn Bioscience Inc., a biotechnology company focused on the discovery and development of novel medicines derived from evolved small molecule natural products, today announced that it has completed a round of financing that was co-funded by Pfizer R&D Innovate and Genesys Capital. In addition, the company has announced a research collaboration with Pfizer Inc.

Pre-CAAP company Steadiwear's Steadiglove was featured as a technology that stood out for Senior Care at the Aging 2.0 Conference this past November in San Francisco. 

Johnson & Johnson Innovation facilitated an exclusive feasibility study between Janssen Research & Development, LLC and WinterLight Labs. The research will evaluate WinterLight’s proprietary technology for analyzing voice samples obtained from Janssen Research & Development’s ongoing clinical trials in Alzheimer’s and neurodegenerative diseases.

In 2017-18, $5.47 million will be distributed to 12 projects through the Health Technologies Fund. 3 CAAP companies are among the Health Innovation project teams which received funding. Congratulations to Komodo OpenLabs, Eve Medical and BrainFx!